Literature DB >> 2870153

Alpha-adrenoceptor blocking activity of fenoldopam (SK&F 82526), a selective DA1 agonist.

S Nakamura, J D Kohli, S I Rajfer.   

Abstract

The alpha-adrenoceptor blocking activity of fenoldopam (SK&F 82526), a selective dopamine vascular receptor (DA1) agonist, was evaluated in isolated segmental preparations of rabbit aorta, dog mesenteric and rabbit splenic arteries. Fenoldopam, in concentrations ranging from 10(-6) to 10(-4) M, produced parallel, dextral shifts of concentration-contractile response curves to noradrenaline. Slopes of the Schild regression lines were not significantly different from unity in the three vessels. pA2 values for fenoldopam in the rabbit aorta, dog mesenteric and rabbit splenic arteries were 5.48 +/- 0.08, 5.78 +/- 0.05, and 5.20 +/- 0.05, respectively. In experiments where the drug was added to the bathing medium before exposing the vascular segments to the irreversible alpha-adrenoceptor antagonist, phenoxybenzamine, fenoldopam provided nearly complete protection against alpha-adrenoceptor blockade. These results demonstrate that fenoldopam possesses alpha-adrenoceptor antagonist activity and competes with alpha-phenoxybenzamine, for occupancy at the same receptor site.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2870153     DOI: 10.1111/j.2042-7158.1986.tb04522.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  4 in total

1.  Renal vasodilatation by dopexamine and fenoldopam due to alpha 1-adrenoceptor blockade.

Authors:  S W Martin; K J Broadley
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

2.  Influence of the dopamine receptor agonists fenoldopam and quinpirole in the rat superior mesenteric vascular bed.

Authors:  A G Dupont; R A Lefebvre; P Vanderniepen
Journal:  Br J Pharmacol       Date:  1987-07       Impact factor: 8.739

Review 3.  Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies.

Authors:  R N Brogden; A Markham
Journal:  Drugs       Date:  1997-10       Impact factor: 9.546

Review 4.  Vasodilator therapy without converting-enzyme inhibition in congestive heart failure--usefulness and limitations.

Authors:  W J Remme
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.